A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
The firm reports it had the highest flu revenue in the fourth quarter since the pandemic flu outbreak of 2009.
The project, the first under a partnership between the university and Illumina announced last year, will apply whole-genome sequencing to challenging cancers types.
The Centers for Disease Control and Prevention says one of the test reagents will likely need to be remanufactured in its labs.
The firms will collaborate to develop a blood collection device and automated sample handling and analytic technologies for use in decentralized testing.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.
Following a lengthy discovery period, the lab is asking a South Carolina federal district court to find in its favor and decide that its negligence did not result in the death of Williams' son.
The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.
The company will use the money to acquire PCR equipment to be used in connection with sales of reagents for infectious disease tests, among other uses.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.
Qiagen, which is also developing a single-plex qRT-PCR assay for 2019-nCoV, said it will have a syndromic panel including targets for the virus ready this month.
The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The company filed the application based on the PAOLA-1 data, which showed HRD-positive ovarian cancer patients saw pronounced benefit from the combo.
The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.
The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.
The technology uses single-cell droplet digital PCR to analyze maternal blood cell populations that have been enriched for fetal cells by MACS.
Initially, FIND and the WHO will work to develop national essential diagnostics lists, as well as to collect data to support countries in their aim to provide universal health coverage.
The Seoul-based firm said its PCR-based test kit is the first novel coronavirus assay to be granted emergency use authorization in Korea.